The anti-Parkinson drug, rasagiline (N-propargyl-(1R)-aminoindan) promotes neuronal survival, via neuroprotective activity related to its propargyl moiety (propargylamine). We have investigated the neurorescue effects of propargylamine, in a progressive neuronal death model, induced by long-term serum deprivation in human SH-SY5Y neuroblastoma cells. Propargylamine (0.1-10 μM) dose-dependently reduced the levels of the early apoptosisassociated phosphorylated protein, H2A-X (ser 139), as well as decreased the cleavage of caspase-3 and its substrate poly-ADP ribose polymerase (PARP). In addition, the compound markedly reversed the apoptotic effects induced by long-term serum withdrawal, including down-regulation of the antiapoptotic protein, Bcl-2, as well as up-regulation of the proapoptotic proteins, Bax, Bad, and Bim. Real-time RT-PCR demonstrated that propargylamine elevated gene expression levels of Bcl-2, and the neurotrophic factors glial cell line-derived neurotrophic factor (GDNF) and brain-derived neurotrophic factor (BDNF) and reduced Bax gene expression. Serum deprivation increased mRNA and protein levels of holo-amyloid precursor protein (APP), which was markedly decreased by propargylamine. This was accompanied by inducing the release of the nonamyloidogenic α-secretase form of soluble APP (sAPPα) into the medium. Similar effects on cell survival and APP regulation/processing were demonstrated for rasagiline. These results indicate that both rasagiline and propargylamine possess neurorescue activity, associated with regulation of Bcl-2 family proteins, neurotrophic factors, and APP metabolism.
underlying the prevention of neuronal cell death associated with such destructive diseases in the central nervous system. Apoptotic signaling is a multistep pathway initiated by opening a mitochondrial megachannel, called permeability transition pore (PT), followed by a decline in mitochondrial membrane potential (ΔΨm), release of cytochrome c and apoptosis-induced factors (AIF) (1, 2) . PT is regulated by the antiapoptotic proteins Bcl-2 and Bcl-xL and proapoptotic Bax analogous disrupting ΔΨm. These events activate cysteine-dependent, aspartate-specific protease (caspases) that acts as effectors and executioners of apoptosis (3, 4) . Activation of the cysteine protease caspase-3 appears to be a key event in the execution of apoptosis in the central nervous system (5) .
A series of drugs have been proposed as candidates of neuroprotective agents for neuroprotection trails (6) . Among them, rasagiline (N-propargyl-(1R)-aminoindan), a highly potent selective irreversible monoamine oxidase (MAO)-B inhibitor, anti-Parkinsonian drug (7, 8) and related propargylamines exert neuroprotective effects against a variety of insults in both in vitro (2, (8) (9) (10) (11) (14) (15) (16) and in vivo models (12, 13, 17, 18) . Recent clinical studies with rasagiline in Parkinsonian subjects have shown that patients treated with rasagiline for 12 months show significantly less functional decline than those whose treatment was delayed by 6 months. This may suggest that rasagiline may possess disease modifying activity that could be related to cell culture and animal neuroprotective studies so far described (19) . It was recently shown that free propargylamine, similar to rasagiline, exerts a neuroprotective activity against apoptosis induced by serum withdrawal (16) and the endogenous neurotoxin, N-methyl(R)salsolinol (15) . The neuroprotective mechanism involves activation of protein kinase c (PKC) α and ε and is associated with regulation of the Bcl-2 family proteins and mitochondrial membrane stabilization (20, 21) .
A link between apoptosis and the regulation of APP processing has been suggested, as APP processing represents a crucial step in the molecular cascade of events leading to AD pathogenesis (22) . APP, a type I of transmembrane glycoprotein, is metabolized by several pathways mediated alternatively by either α-or β-and γ-secretases (see review (23) ). The secretory pathway involves an α-secretase, extracellular cleavage of APP within the Aβ domain, thereby preventing the formation of 4 kDa Aβ, and generates a soluble nonamyloidogenic fragment (sAPPα) and a 10 kDa cell-associated C-terminal peptide, which can be further processed into a secreted nonamyloidogenic 3 kDa Aβ peptide. β-secretase cleaves at the N terminus of the Aβ sequence and generates a cell-associated β-C-terminal fragment, which is then processed by γ-secretase, giving rise to the generation of the amyloidogenic peptide, Aβ. The formation of Aβ aggregates is thought to initiate the pathogenic cascade, leading ultimately to neuronal loss and dementia (24, 25) . Accumulation of Aβ can result in oxidative stress, inflammation, and neurotoxicity, all of which lead to apoptosis and the deterioration of neurotransmission system seen in AD (26) (27) (28) . During neuronal apoptosis, APP, and Aβ formation are enhanced and the nonamyloidogenic pathway decreases (29) . In addition, overexpression of APP increases the formation of amyloidogenic peptides in cell cultures and causes neurodegeneration and cognitive dysfunction in transgenic mice (30) (31) (32) .
Rasagiline and rasagiline-related derivatives, such as the anti-Alzheimer drug ladostigil (TV3326) (33) induced the release of the neuroprotective-neurotrophic nonamyloidogenic sAPPα by the mitogen-activated protein kinase (MAPK)-and PKC-dependent mechanisms in vitro (34, 35), as well as reduced holo-APP levels in mice hippocampus (20) . This process was shown to be associated with the propargyl moiety of these drugs, since propargylamine has a similar mode of action with the same potency of rasagiline (16) .
The present study describes new aspects of the prosurvival effects of propargylamine in longterm serum deprivation, neurorescue model, using SH-SY5Y neuroblastoma cells. Our results show that propargylamine has a potent neurorescue activity via down-regulation of Bax, Bad, and Bim and induction of Bcl-2, as well as the neurotrophic factors GDNF and BDNF. Moreover, propargylamine not only reduced the expression of amyloidogenic holo-APP, but also induced the release of the neuroprotective-neurotrophic nonamyloidogenic sAPPα.
MATERIALS AND METHODS

Materials
Propargylamine and rasagiline [N-propargyl-(1R)-aminoindan] were kindly donated by Teva Pharmaceutical, Israel (Netanya, Israel). Electrophoresis reagents were obtained from Invitrogen (Carlsbad, CA). Tissue culture reagents were purchased from Biological Industries (BethHaemek, Israel). Caspase-3, Bad, Bim, and Bax antibodies were provided from Cell Signaling, (Beverly, MA), and those against PARP and anti-phospho-histone H2A.X were purchased from Upstate, (Charlottesville, VA). Bcl-2 antibody was purchased from BD, Biosciences Transduction Laboratories, (Heidelberg, Germany). Anti-APP (22C11) and Anti-Aβ, amino acid residue 1-17 (6E10) antibodies were obtained from Chemicon International (Temecula, CA). Anti-APP, C-terminal antibody, β-actin antibody, and all other chemicals were purchased from Sigma Chemical (St. Louis, MO).
Tri Reagent Isolation reagent was purchased from Sigma Chemical (St Louis, MO). RT reaction mix, random hexanucleotides, dNTP, RNasin inhibitor and M-MLV reverse transcriptase were purchased from Promega (Madison, WI) The LightCycler, DNA Master SYBR Green I ready-to use PCR mix kit and Faststart (Hot Start) DNA (Roche Diagnostics, Mannheim, Germany).
Cell culture and viability measurements
Human SH-SY5Y neuroblastoma cells were plated in 100-mm culture dishes and cultured in Dulbecco's modified Eagle's medium (DMEM) (4500 mg/l glucose), containing 10% FCS and a mixture of 1% penicillin/streptomycin/nystatin. Cell cultures were incubated at 37°C in a humid 5% CO 2 -95% air environment.
When cells reached the required confluence, they were seeded (2×10 6 ) onto 100 mm plates in culture medium supplemented with full serum for 1 day at 37°C. Continuously, the medium was replaced into serum deprived medium for 3 days and further on, the cells were incubated with or without various concentration of drugs in fresh serum-free medium for additional 2 days at 37°C. Cells incubated with full serum medium were used as a control.
A cell death detection ELISA kit (Roche Molecular Biochemicals, Indianapolis, IN) was used to detect apoptosis. The assay is based on a quantitative sandwich ELISA, with antibodies directed against DNA and histones to detect mono-and oligonucleosomes in the cytoplasm of cells undergoing apoptosis. The ELISA was performed according to the manufacturer's protocol. The absorption was determined in a Tecan Sunrise Elisa-Reader (Hombrechtikon, Switzerland) at λ = 405/490 nm after automatic subtraction of background readings. Results are expressed as folds of the control values.
Immunoblot analyses
For Western blot analyses, attached cells were lysed in 1× nonreducing Laemmli buffer followed by boiling for 3−5 min. Protein content was determined using the Bradford method. Equal amounts of protein were separated by SDS-PAGE and blotted onto polyvinylidene difluoride membranes (Millipore). Membranes were treated with blocking buffer (5% dry milk in PBS or 5% dry milk, 0.05% Tween 20 in TBS). Primary antibodies were diluted in PBS or in TBS containing 5% BSA, 0.05% Tween 20 and incubated with membranes for 20 h at 4°C followed by incubation (1 h at room temperature) in dilutions of horseradish peroxidase-conjugated secondary antibodies in the same buffer. Detection was achieved using Western blotting detection reagent, ECL (Amersham, Pharmacia, Little Chalfont Buckinghamshire, UK). Quantification of the results was accomplished by measuring the optical density of the labeled bands from the autoradiograms, using the computerized imaging program Bio-1D (Vilber Lourmat Biotech. Bioprof., Marine la Vallee, France). The values were normalized to β-actin intensity levels.
Total RNA extraction, reverse transcription, and quantitative real-time RT-PCR
Isolation of total RNA was performed, using Tri-Reagent Isolation reagent, according to the manufacturer's protocol (Sigma Chemical). Total RNA was treated with DNase-RNase free (Roche Diagnostics) for 30 min at 37°C, and subsequently extracted by a round of phenol:chloroform: isoamylalcohol (25:24:1), followed by one of chloroform. After precipitation with NaOAc (0.3 M) and ethyl alcohol, the RNA pellet was washed with 80% ethyl alcohol (12,000 g) for 10 min and resuspended in 100 μl of diethylpyrocarbonate (DEPC)-treated water and incubated for 10 min at 56°C to facilitate resuspension.
Total RNA (2 µg) was denatured and reverse transcribed using random hexanucleotides (0.5 µg/µl), as described previously (16) .
Quantitative real-time PCR, using LightCycler and FastStart DNA Master SYBR Green I readyto-use PCR mix, was performed according to the manufacturer's protocol (Roche Diagnostics). cDNA (40 ng) was amplified in 20 μl total volume. The sequences of the primers and the size of the products are described in Table 1 . The results are analyzed on the provided program of the LightCycler. The relative expression level of a given mRNA was assessed by normalizing to the housekeeping gene 18S-rRNA and comparing with control values.
Two-dimensional polyacrylamide gel electrophoresis (PAGE) and immunoblot analysis
Two-dimensional PAGE was performed under conditions essentially as described by the manufacturer's protocol (Bio-Rad, Hercules, CA, USA), using 110-mm pH 3-10 immobilized pH gradients (IPG) strips and Criterion (4−20% gels). Protein samples were dissolved in buffer containing 7 M urea, 2 M thiourea, 65 mM dithiothreitol, 0.125% (v/v) Biolytes 3-10, 2% CHAPS, and bromophenol blue. For the first-dimension separation, 200 µg of protein were applied to a dehydrated IPG strip, and isoelectric focusing was carried out at room temperature as follows: passive dehydration for 1 h and then at linear gradient from 50 V until 8000 V for 12 h. Subsequently, strips were placed on Criterion gels and the second-dimension separation was carried out at 200 V for 75 min. After electrophoresis, the resulting gels were electroblotted onto nitrocellulose paper, and Western blotting analysis was performed with a specific antibody to identify Anti-Alzheimer Precursor Protein (APP-22C11) obtained from Chemicon International (Temecula, CA).
Statistics
One-way ANOVA, followed by the Tukey test, or Student t test, were performed using the scientific statistic software GraphPad Instant version 2.04. P values of less than 0.05 were considered significant.
RESULTS
Propargylamine reduced proapoptotic proteins following long-term serum withdrawal
Recent studies on structure-activity relationship among rasagiline-related compounds have revealed the importance of the propargyl moiety for neuroprotection (16) . The present study evaluated the neurorescue effects of propargylamine in an extreme apoptotic model of human SH-SY5Y neuroblastoma cells following prolonged serum deprivation. In this model, SH-SY5Y cells were placed in serum-free medium for 3 days, and then incubated without or with propargylamine (0.1-10 μM) for an additional 2 days. Cells placed in full-serum medium served as a control. Initially, we examined the cell viability and cleavage of caspase-3, known to play a central role in the execution of apoptosis (36). Indeed, in this model system, SH-SY5Y neuroblastoma cells, exposed to long-term serum deprivation, exhibited a significant increase in the levels of the activated form of caspase-3 (1.72±0.15 fold, P<0.01, vs. full serum, control), as well as in the cleavage of the caspase substrate, PARP (1.82±0.32 fold, P < 0.01, vs. control) (Fig. 1A) . Treatment with propargylamine 0.1 and 1 µM significantly reversed the apoptotic effect on activation of caspase-3 (59±7.1% and 65±6.0%, P<0.05, of serum-free culture, respectively), and on the cleavage of PARP (54±12% and 70±5.0%, P<0.05, of serum-free culture, respectively) (Fig. 1A) . The propargylamine-induced decrease in the levels of cleaved caspase-3 and PARP exhibited a biphasic dose-response dependency, as has been demonstrated recently (16) .
In addition, long-term serum deprivation caused apparent increase in serine-139 phosphorylation of H2A.X, which was shown to occur early in apoptosis, concurrently with the initial appearance of high molecular weight DNA fragments (2.17±0.02 fold, P<0.001, vs. full serum, control) (Fig. 1B) (37). Consistent with its effect on the apoptotic markers, cleaved caspase-3 and PARP, propargylamine (0.1 and 1 µM) significantly decreased H2A.X levels (43±10% and 67±0.4%, P<0.001, of serum-free culture, respectively). 10 µM propargylamine was not significantly effective (Fig. 1B) .
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In these apoptotic conditions, cell viability was markedly reduced (9.48±1.1 fold, P<0.001, vs. control). Treatment with propargylamine (1 µM) significantly reduced cell death induced by serum deprivation, as assessed by an apoptotic cell death detection ELISA (Fig. 1C) .
Effects of propargylamine on Bcl-2 and Bax gene expression and protein levels
Considering the importance of Bcl-2 and Bax in the regulation of programmed cell death pathway, the effects of propargylamine on gene expression, as well as protein levels of these molecules were determined. RNA was extracted from SH-SY5Y neuroblastoma cells, treated without or with propargylamine (0.1-10 μM), as described in Materials and Methods. Each gene expression was normalized to the housekeeping gene, 18S-rRNA, since this transcript was reported to be less susceptible to the influence by external factors (38). Real-time RT-PCR revealed that the Bcl-2/Bax mRNA expression ratio was markedly reduced following long-term serum withdrawal (33±11%, P<0.01 vs. full serum, control, data not shown). Treatment with propargylamine for 2 days significantly increased Bcl-2 mRNA level, while markedly reducing Bax gene expression vs. serum-free culture ( Fig. 2A) . The Bcl-2/Bax mRNA ratio showed a significant increase following treatment with propargylamine (at 1 μM: 8.5±0.68-fold, P<0.05 vs. serum-free culture) ( Fig. 2A ).
In consistence with the gene expression results, Western blotting analysis showed that in serumfree culture, Bcl-2 protein levels were decreased and conversely, Bax protein levels were increased (Fig. 2B, top) . The Bcl-2/Bax protein ratio was markedly reduced (20±3.0%, P<0.001 vs. control) (Fig. 2B) . Propargylamine increased Bcl-2 levels and reduced Bax levels. The Bcl-2/Bax ratio showed a significant increase following treatment with propargylamine, compared with serum-free culture (Fig. 2B) .
Propargylamine reduced the levels of the "BH3-only" proteins, Bad and Bim
We further examined the effect of propargylamine on the expression of the proapoptotic "BH3-only" proteins of the Bcl-2 family proteins, Bad and Bim, previously shown to be regulated by growth factors withdrawal (21, 36, 39) . Indeed, long-term serum deprivation significantly induced the expression of both Bad and Bim levels by 2.7 fold and 1.8 fold vs. full serum, control, respectively (Fig. 3) . Treatment of SH-SY5Y neuroblastoma cells with propargylamine markedly reversed these effects (Fig. 3) . Specifically, 0.1 and 1 μM propargylamine reduced Bad protein levels by 69 ± 1.1%, P < 0.01 and 65 ± 6.0%, P < 0.001, of serum-free, respectively, as well as, Bim protein levels by 79 ± 6.0% and 48 ± 19%, P < 0.05, of serum-free, respectively. 10 µM propargylamine did not significantly affect either Bad or Bim levels (Fig. 3) .
Effects of propargylamine on GDNF and BDNF gene expression
To further evaluate the mechanism of propargylamine-neurorescue activities, we examined the changes in cell-survival genes, including the neurotrophic factors, GDNF and BDNF. The realtime RT-PCR consists of RNA isolated from SH-SY5Y neuroblastoma cells, maintained in serum-free media for 3 days, and then treated without or with propargylamine (0.1-10 μM) for an additional 2 days. Cells placed in full-serum medium served as control. Each gene expression was normalized to the housekeeping gene, 18S-rRNA. Both GDNF and BDNF mRNA levels were unchanged following serum withdrawal (Fig. 4A, B) . However, propargylamine (0.1 and 1
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μM) significantly increased mRNA expression levels of GDNF (Fig. 4A) , as well as of BDNF (Fig. 4B) . Ten micromoles propargylamine was not significantly effective.
Neurorescue effects of rasagiline against long-term serum withdrawal-induced neuronal death
The propargyl-containing drug, rasagiline, exerts an antiapoptotic activity against a variety of insults in cell culture and in vivo models (16, (40) (41) (42) (43) . In the present study, we also examined the mechanism involved in the neurorescue effects of rasagiline. Similar to propargylamine, treatment of SH-SY5Y neuroblastoma cells with rasagiline (1 μM) markedly decreased cleaved caspase-3 and PARP (69±4.0%, P<0.001 and 78±4.0%, P<0.01, of serum-free culture, respectively) (Fig. 5A) . Rasagiline (1 μM) also suppressed the levels of apoptosis-associated phosphorylation of H2A.X protein (71±14%, P<0.01, of serum free culture) (Fig. 5A ). In addition, rasagiline (1 μM) induced protein levels of Bcl-2 (~1.8 fold, vs. serum-free culture) and reduced those of Bax, Bad, and Bim (~75% of serum-free culture) (Fig. 5B ).
Propargylamine and rasagiline regulated holo-APP levels and sAPPα release following long-term serum deprivation
Neuronal insults increase the levels of holo-APP, in consistent with the pathophysiology of AD (44) (45) (46) . Similarly, we demonstrate in the present study that apoptosis, induced by exposure of SH-SY5Y cells to long-term serum withdrawal, resulted in a significant increase in holo-APP gene expression (1.67±0.14-fold, P<0.01 vs. full serum, control) (Fig. 6A) , as well as in protein levels (2.13±0.26-fold, P<0.05 vs. full serum, control) (Fig. 6B) .
Recently, we have reported that propargyl-derivatives regulate holo-APP levels in vivo (20) . Thus, we further examined whether propargylamine could have regulatory effects on holo-APP levels in the current neurorescue model. Indeed, propargylamine significantly down-regulated holo-APP protein levels in SH-SY5Y cells, using holo-APP N-terminal antibody, 22C11 (at 1 μM: 63±7.0%, P<0.01 of serum-free culture) (Fig. 6B) . The effect of propargylamine on holo-APP levels was further confirmed using anti-APP C-terminal antibody (at 1 μM: 60±4.0%, P<0.001 of serum free culture) (Fig. 6C) . However, propargylamine did not affect holo-APP mRNA levels (Fig. 6A) , indicating post-transcriptional regulatory mechanism, as has been described previously (46, 47) . Similar to propargylamine, rasagiline (1 μM) reduced protein levels of holo-APP, demonstrated with both 22C11 and anti-APP C-terminal antibodies (75±2.0%, P<0.001 and 72±3.0%, P<0.01 of serum-free culture, respectively) (Fig. 7A, B) . Using two-dimensional PAGE and immunoblotting assay, we detected several holo-APP forms in cell lysate, which migrated at molecular weight of 110-130 kDa and at isoelectric point of ~4.5 (Fig. 8) . The wide range of APP isoelectric forms is most likely due to different posttranscriptional modifications (48, 49) . We demonstrated that long-term serum withdrawal markedly increased the levels of holo-APP forms (Fig. 8A, B) , while both propargylamine and rasagiline clearly decreased them (Fig. 8C, D) . Further studies would be necessary to analyze each of these holo-APP modifications.
In addition, because rasagiline and its derivative drugs were shown to stimulate the release of the nonamyloidogenic α-secretase form of sAPPα via activation of PKC and MAPK pathway (34), the effect of propargylamine on sAPPα release was further analyzed in the long-term serum-
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deprived model. Consistent with our previous results, both propargylamine and rasagiline increased sAPPα levels in the medium of serum-deprived SH-SY5Y cells (Fig. 6D and 7C , respectively). Specifically, propargylamine (1 μM) increased sAPPα by 3.0 ± 0.8-fold, P < 0.05 vs. serum-deprived cells (Fig. 6D) , and rasagiline (1 μM) increased sAPPα by 1.69 ± 0.27-fold, P < 0.05 vs. serum-deprived cells (Fig. 7C) .
DISCUSSION
The present study demonstrates the regulation of Bcl-2 family proteins, neurotrophic factors, and APP processing in the neurorescue activity of propargylamine (Fig. 9) .
Although not fully proven, it is widely regarded that apoptosis may be involved in a number of progressive neurodegenerative disorders, such as PD and AD (22) . Because diagnosis of neurodegenerative diseases is based on the appearance of clinical characteristics, patients have already suffered massive neuronal degeneration. Only 10% to 30% of normal neuronal population is surviving in the clinical stage of the disease (50) . Therefore, there is a significant effort to develop drugs with neurorescue activity for therapy in the clinically diagnostic patients.
To study the mechanism of apoptosis, the serum deprivation model has been characterized in several neuronal cell types, such as cerebral granule neurons of mouse (51, 52), human SK-N-SH and SH-SY5Y neuroblastoma cells (53) (54) (55) , and rat PC-12 cells (16) . In this study, using human SH-SY5Y neuroblastoma cells, we established a prolonged serum deprivation-neurorescue model, in which the cells were exposed to serum-free media 3 days before the administration of drugs. In these extreme serum-deprived conditions, the severe loss of viability was due to apoptotic cell death, detected by a significant up-regulation of apoptotic-associated parameters, including cleaved caspase-3 and PARP and H2A.X. In addition, we have found that in this model, gene and protein expression of the anti-apoptotic Bcl-2 were down-regulated, whereas, those of the proapoptotic Bax were up-regulated, consistent with the notion that the ratio of Bcl-2 to Bax predetermines the susceptibility of the cell to a given apoptotic stimulus (56) . We have also found that the potent proapoptotic "BH3-only" proteins, Bad and Bim, were up-regulated following prolonged serum withdrawal, in accordance with previous studies demonstrating the regulatory effect of growth factors withdrawal on these proteins (21, 36, 39) . These observations indicate that serum deprivation-induced cell death could serve as an effective model system for screening potential neuronal survival agents in neurorescue research. Additionally, in this model, gene expression and protein levels of holo-APP were significantly up-regulated, in keeping with increased holo-APP levels found following neuronal insults, such as iron stimulation (46), low glucose concentration (57), heat shock (58), and serum (44) or cellular energy depletion (59) . In addition, induced holo-APP levels were demonstrated after various brain damages (60) (61) (62) (63) (64) (65) (66) , in consistence with the pathophysiology of AD (45, 67) .
Previous studies have shown that the selective MAO-B inhibitor, anti-Parkinson drug, rasagiline, has a broad neuroprotective activity against a variety of neurotoxins in neuronal cell culture and in vivo models (16, (40) (41) (42) (43) . Moreover, the free propargyl moiety of rasagiline, propargylamine, exerts neuroprotective activity against N-methyl(R)salsolinol (68) , as well as serum deprivationinduced cell death (21) , suggesting that the propargyl moiety of rasagiline is essential for neuroprotection. This study describes, for the first time, the neurorescue effects of propargylamine, given 3 days after serum withdrawal, characterized by the reduction in the cleavage of caspase-3 and PARP, as well as in phosphorylated histone, H2A.X levels. The prosurvival effects of propargylamine were mediated by the Bcl-2 family proteins, thus increasing both Bcl-2/Bax ratio of mRNA and protein levels and reducing the "BH3-only" proteins, Bad and Bim. Similar prosurvival, neurorescue effects were also found for rasagiline. These results are consistent with our previous published works, providing evidence for the neuroprotective mechanism of rasagiline and propargylamine, mediated by PKC-MAPK-dependent activation. Both compounds regulated the PKC isoforms, PKCα and PKCε, involved in cell survival pathway, while down-regulating detrimental PKCγ (16) . Activation of PKCε and PKCα was shown to increase the expression of anti-apoptotic Bcl-2 family proteins (69, 70) , which stabilize the mitochondrial membrane permeability transition pore (MPTp), thus preventing apoptosis by maintaining ΔΨm (2, 71) . Indeed, both rasagiline and propargylamine prevent the fall in ΔΨm, swelling of mitochondria matrix and opening of MPTp in SH-SY5Y cells exposed to the endogenous neurotoxin, N-methyl(R)salsolinol (2).
As another mechanism of neurorescue, propargylamine was found to up-regulate gene expression levels of GDNF and BDNF following long-term serum deprivation of SH-SY5Y cells. Indeed, both neurotrophic factors have been shown to induce neuroprotective and neurorescue activity in dopaminergic and cholinergic neurons and promote survival of major neuronal types affected in AD and PD (72, 73) . Recently, rasagiline was proved to increase the protein and mRNA levels of GDNF in SH-SY5Y neuroblastoma cells through activation of nuclear factor-kappaB (NF-kappaB) transcription factor (41). Moreover, we reported that rasagiline up-regulated BDNF gene expression in serum-starved PC12 cells (16) . These results indicate that the induction of neurotrophic factors by propargylamine and propargyl-related derivatives might suppress apoptosis in neurodegenerative diseases.
Studies on structure-activity relationships have indicated the crucial role of the propargyl moiety in the neuroprotective activity of rasagiline and its derivatives. However, the neuroprotective activity of rasagiline and propargylamine does not depend on their MAO inhibitory potency since propargylamine is a very poor inhibitor of MAO (IC 50 >50 μM), and the S-isomer of rasagiline, TVP1022, which is not an inhibitor of MAO-A or B was also found to be neuroprotective in both in vivo and in vitro models (8, 11, 15) . Moreover, the MAO inhibitory action is at higher concentrations than those required for neuroprotective/neurorescue activity of these compounds (68) .
In AD, a growing body of evidence suggests that increased expression and/or altered processing of APP play a central role in amyloidogenesis processes, leading to the formation of the senile plaque (74, 75) . A common mechanism leading to up-regulation of holo-APP expression and Aβ formation is the shortage of energy supply, related oxidative stresses, and apoptosis. Ischemia, hyperglycemia, traumatic brain injury, and cellular energy depletion have been shown to promote holo-APP expression and to route its metabolism from the nonamyloidogenic to the amyloidogenic pathway (57) (58) (59) (60) (61) (62) (63) (64) (65) (66) . Thus, the observation that propargylamine and rasagiline markedly decreased the levels of holo-APP could be of a value in reducing Aβ formation. In agreement, our recent in vivo studies demonstrated that rasagiline and its anti-Alzheimer cholinesterase-brain selective MAO inhibitor derivative, ladostigil (76) reduced the levels of cell-associated holo-APP in mice hippocampus (20) . The regulatory mechanism of propargylamine on holo-APP expression is presumably post-transcriptional, since the drug suppresses holo-APP protein levels without altering mRNA expression. There are now several reports supporting an important role for translational regulatory mechanism to control APP synthesis and probably Aβ peptide secretion through the 5′-untranslated region (5′-UTR) of the precursor transcript (46, 47) . Further studies would reveal whether propargylamine and rasagiline regulate holo-APP through inhibition of APP translation, mediated through the APP 5′-UTR. In addition, propargylamine, rasagiline and ladostigil stimulated sAPPα release into the medium in vitro via PKC-MAPK signaling pathway (34, 35). As previously shown, the sAPPα fragment, derived from the nonamyloidogenic processing pathway, is neuroprotective and neurotrophic, and it regulates cell excitability and synaptic plasticity (75) .
In conclusion, we provide evidence that it is the propargyl moiety of propargylamine-related derivatives that rescues degenerative neurons from apoptosis. The present findings may support a possible disease-modifying activity of rasagiline, as suggested in clinical trials of early PD patients (19) . neuroblastoma cells were placed into serum-free media for 3 days and then incubated without or with propargylamine (0.1−10 μM) for an additional 2 days (as described in Materials and Methods). Cells incubated with full serum media were used as a control. A) Caspase-3 and PARP cleavage, and B) H2A.X levels in cell lysates were analyzed by Western blotting. The loading of the lanes was normalized to levels of β-Actin, and the experiment is representative of 3 independent experiments. C) Cell death detection ELISA was applied and the results are the means ± SEM (n=3). #P < 0.001 vs. control; *P < 0.05 vs. serum withdrawal cultures. were placed into serum-free medium for 3 days, and then incubated without or with propargylamine (0.1−10 μM) for an additional 2 days. Cells incubated with full serum media were used as a control. A) Bcl-2 and Bax gene expression was measured by quantitative real-time RT-PCR, and the ratios of Bcl-2 mRNA to Bax mRNA are calculated. The amount of each product was normalized to the housekeeping gene 18S-rRNA. B) Western blots of protein levels of Bcl-2 and Bax followed by quantitated results and the ratios of Bcl-2/Bax. The loading of the lanes was normalized to levels of β-Actin, and the quantitated results are presented relative to serum-free values. Data are expressed as means ± SEM (n=3). *P < 0.05, **P < 0.01 and ***P < 0.001 vs. serum withdrawal cultures. neuroblastoma cells were incubated in serum-free media without or with rasagiline (1 µM) in the neurorescue model, as described in Fig. 3 . A) Caspase-3 and PARP cleavage and H2A.X levels as well as B) Bcl-2 family protein levels were analyzed in cell lysates by Western blotting. The loading of the lanes was normalized to levels of β-Actin. 6 . Regulatory effects of propargylamine on holo-APP levels and sAPPα release following long-term serum withdrawal. SH-SY5Y neuroblastoma cells were placed into serum-free medium for 3 days and then incubated without or with propargylamine (0.1−10 μM) for an additional 2 days. Cells incubated with full serum media were used as control. A) Gene expression of holo-APP was measured by quantitative real-time RT-PCR. The amount of each product was normalized to the housekeeping gene 18S-rRNA. B, C) holo-APP protein levels were analyzed in cell lysates by Western blotting using either 22C11 or anti-APP, C-terminal antibodies, respectively. The loading of the lanes was normalized to levels of β-Actin. D) Western blots of sAPPα were measured in the media, using 6E10 antibody. Data are representative of 3 independent experiments. **P<0.01 vs. full serum, control. SH-SY5Y neuroblastoma cells were incubated in serum-free media without or with rasagiline (1 μM) in the neurorescue model, as described in Materials and Methods. Western blots of holo-APP protein levels were analyzed in cell lysates using either A) 22C11 or B) anti-APP, C-terminal antibodies. The loading of the lanes was normalized to levels of β-Actin. C) sAPPα was measured in the media using 6E10 antibody. Data are representative of 3 independent experiments. 
